Nilo Therapeutics Secures $101M for Neuro-Immunology Revolution
October 15, 2025, 3:41 pm
Location: United States, Washington, Seattle
Employees: 1001-5000
Founded date: 2000
Nilo Therapeutics launched with $101 million Series A funding. The neuro-immunology biotech seeks to restore immune balance. It modulates neural circuits, targeting autoimmune and inflammatory diseases. Key investors include The Column Group, DCVC Bio, and Lux Capital. Kim Seth, Ph.D., leads as CEO. Laurens Kruidenier, Ph.D., serves as CSO. Funds will establish New York City labs, expand R&D, and advance preclinical programs. Nilo pioneers a new drug class. It focuses on brain-body circuits, avoiding direct immune suppression. This approach integrates neuroscience and immunology.
Nilo Therapeutics entered the biotechnology landscape. It arrived with significant financial backing. The company secured $101 million in Series A funding. This investment propels Nilo's mission. It aims to revolutionize treatment for immune-related diseases. Nilo focuses on neuro-immunology. Its core strategy involves restoring immune balance. This is achieved through precise neural circuit modulation.
The substantial funding round drew prominent investors. The Column Group, DCVC Bio, and Lux Capital co-led the financing. Additional support came from the Gates Foundation. Alexandria Venture Investments also contributed. This capital infusion is vital. It will establish Nilo’s research laboratories in New York City. It will also expand its interdisciplinary R&D team. Crucially, it accelerates development of preclinical programs.
Nilo’s scientific foundation is robust. It rests on discoveries from leading academic minds. Charles Zuker, Ph.D., from Columbia University, is a co-founder. Ruslan Medzhitov, Ph.D., from Yale University, also contributed. Steve Liberles, Ph.D., from Harvard University, completes the founding trio. These scientists are pioneers in neuro-immunology. Their work translates cutting-edge research into new therapeutic strategies. This collaborative effort formed with The Column Group.
The company's approach marks a paradigm shift. Traditional treatments often suppress the immune system directly. Nilo takes a different path. It modulates neural circuits that naturally regulate immune responses. Specifically, Dr. Zuker's lab identified key vagal neurons. These neurons act as master regulators of systemic inflammation. By targeting these brain-body circuits, Nilo influences multiple immune pathways simultaneously. This method promises several advantages. It could reduce therapeutic resistance. It might also expand treatment options. This applies to a wide range of autoimmune and inflammatory conditions.
Nilo’s strategy offers broad potential. Many diseases stem from immune dysregulation. These include rheumatoid arthritis, Crohn's disease, and multiple sclerosis. Current therapies often have limitations. They can have significant side effects. They may also lose efficacy over time. Nilo’s neuro-immunology platform offers a novel solution. It harnesses the body's intrinsic regulatory mechanisms. This could lead to more durable and safer treatments.
Leadership for Nilo's ambitious journey is in place. Kim Seth, Ph.D., assumes the role of Chief Executive Officer. He also joins the Board of Directors. Dr. Seth brings extensive experience. He boasts over 25 years in the biopharma industry. His background spans early-stage biotech, public companies, and large pharmaceutical firms. Most recently, he served as Chief Business Officer at Repare Therapeutics. There, he helped scale the company through its IPO. He also led business development efforts. These generated over $250 million in financing and partnerships. These partnerships were valued at over $4 billion. Dr. Seth’s career includes strategic roles at Pfizer and Goldman Sachs. He holds a Ph.D. in Neurobiology from Harvard University.
Dr. Seth partners with Chief Scientific Officer Laurens Kruidenier, Ph.D. Dr. Kruidenier is a seasoned immunology expert. He previously held CSO roles at Cellarity and Prometheus Biosciences. At these firms, he advanced multiple therapies. His focus was autoimmune and inflammatory diseases. Together, Seth and Kruidenier lead Nilo's transition. They move the company from stealth mode into active development. Their combined expertise drives Nilo's scientific and strategic direction.
The initial $101 million investment is a significant starting point. It validates Nilo's scientific premise. It also affirms its leadership vision. The funds will establish state-of-the-art research facilities. These will be located in New York City. Expanding the R&D team means recruiting top talent. This will accelerate the discovery and development process. Advancing preclinical programs is the immediate priority. These programs will test Nilo’s innovative drug candidates.
Nilo Therapeutics aims to pioneer a new class of drugs. These will be neuro-immunology drugs. They could fundamentally reshape disease treatment. The company’s launch signifies a major advance. It integrates neuroscience and immunology. This addresses complex medical challenges. The focus remains on patient benefit. Better, more effective therapies are the goal.
The potential market for Nilo's approach is vast. Autoimmune and inflammatory diseases affect millions globally. The economic burden is immense. Current treatments represent a multi-billion-dollar industry. Nilo’s novel mechanism offers a competitive edge. It provides a different way to restore immune homeostasis. This could capture a significant share of the market. It offers hope for patients with unmet needs.
Nilo’s strategy emphasizes precision. It identifies specific neural pathways. It then modulates them. This targeted approach minimizes systemic side effects. It optimizes therapeutic outcomes. The brain-immune axis is a complex network. Understanding and manipulating it represents a frontier in medicine. Nilo stands at this frontier. It is poised to lead.
The integration of neuroscience and immunology is critical. It moves beyond traditional siloed research. Nilo champions this interdisciplinary approach. It combines deep biological insights with cutting-edge drug development. This holistic view is necessary for complex conditions. It offers a more comprehensive understanding of disease. It also provides innovative therapeutic avenues.
Nilo Therapeutics represents a bold venture. It combines elite scientific founders. It has experienced leadership. It possesses substantial financial backing. This formidable combination positions Nilo for success. The company is poised to make a profound impact. It aims to transform the treatment of immune-driven diseases. The launch of Nilo Therapeutics marks a significant milestone. It promises a future of restored immune balance. It offers new hope for patients worldwide.
Nilo Therapeutics entered the biotechnology landscape. It arrived with significant financial backing. The company secured $101 million in Series A funding. This investment propels Nilo's mission. It aims to revolutionize treatment for immune-related diseases. Nilo focuses on neuro-immunology. Its core strategy involves restoring immune balance. This is achieved through precise neural circuit modulation.
The substantial funding round drew prominent investors. The Column Group, DCVC Bio, and Lux Capital co-led the financing. Additional support came from the Gates Foundation. Alexandria Venture Investments also contributed. This capital infusion is vital. It will establish Nilo’s research laboratories in New York City. It will also expand its interdisciplinary R&D team. Crucially, it accelerates development of preclinical programs.
Nilo’s scientific foundation is robust. It rests on discoveries from leading academic minds. Charles Zuker, Ph.D., from Columbia University, is a co-founder. Ruslan Medzhitov, Ph.D., from Yale University, also contributed. Steve Liberles, Ph.D., from Harvard University, completes the founding trio. These scientists are pioneers in neuro-immunology. Their work translates cutting-edge research into new therapeutic strategies. This collaborative effort formed with The Column Group.
The company's approach marks a paradigm shift. Traditional treatments often suppress the immune system directly. Nilo takes a different path. It modulates neural circuits that naturally regulate immune responses. Specifically, Dr. Zuker's lab identified key vagal neurons. These neurons act as master regulators of systemic inflammation. By targeting these brain-body circuits, Nilo influences multiple immune pathways simultaneously. This method promises several advantages. It could reduce therapeutic resistance. It might also expand treatment options. This applies to a wide range of autoimmune and inflammatory conditions.
Nilo’s strategy offers broad potential. Many diseases stem from immune dysregulation. These include rheumatoid arthritis, Crohn's disease, and multiple sclerosis. Current therapies often have limitations. They can have significant side effects. They may also lose efficacy over time. Nilo’s neuro-immunology platform offers a novel solution. It harnesses the body's intrinsic regulatory mechanisms. This could lead to more durable and safer treatments.
Leadership for Nilo's ambitious journey is in place. Kim Seth, Ph.D., assumes the role of Chief Executive Officer. He also joins the Board of Directors. Dr. Seth brings extensive experience. He boasts over 25 years in the biopharma industry. His background spans early-stage biotech, public companies, and large pharmaceutical firms. Most recently, he served as Chief Business Officer at Repare Therapeutics. There, he helped scale the company through its IPO. He also led business development efforts. These generated over $250 million in financing and partnerships. These partnerships were valued at over $4 billion. Dr. Seth’s career includes strategic roles at Pfizer and Goldman Sachs. He holds a Ph.D. in Neurobiology from Harvard University.
Dr. Seth partners with Chief Scientific Officer Laurens Kruidenier, Ph.D. Dr. Kruidenier is a seasoned immunology expert. He previously held CSO roles at Cellarity and Prometheus Biosciences. At these firms, he advanced multiple therapies. His focus was autoimmune and inflammatory diseases. Together, Seth and Kruidenier lead Nilo's transition. They move the company from stealth mode into active development. Their combined expertise drives Nilo's scientific and strategic direction.
The initial $101 million investment is a significant starting point. It validates Nilo's scientific premise. It also affirms its leadership vision. The funds will establish state-of-the-art research facilities. These will be located in New York City. Expanding the R&D team means recruiting top talent. This will accelerate the discovery and development process. Advancing preclinical programs is the immediate priority. These programs will test Nilo’s innovative drug candidates.
Nilo Therapeutics aims to pioneer a new class of drugs. These will be neuro-immunology drugs. They could fundamentally reshape disease treatment. The company’s launch signifies a major advance. It integrates neuroscience and immunology. This addresses complex medical challenges. The focus remains on patient benefit. Better, more effective therapies are the goal.
The potential market for Nilo's approach is vast. Autoimmune and inflammatory diseases affect millions globally. The economic burden is immense. Current treatments represent a multi-billion-dollar industry. Nilo’s novel mechanism offers a competitive edge. It provides a different way to restore immune homeostasis. This could capture a significant share of the market. It offers hope for patients with unmet needs.
Nilo’s strategy emphasizes precision. It identifies specific neural pathways. It then modulates them. This targeted approach minimizes systemic side effects. It optimizes therapeutic outcomes. The brain-immune axis is a complex network. Understanding and manipulating it represents a frontier in medicine. Nilo stands at this frontier. It is poised to lead.
The integration of neuroscience and immunology is critical. It moves beyond traditional siloed research. Nilo champions this interdisciplinary approach. It combines deep biological insights with cutting-edge drug development. This holistic view is necessary for complex conditions. It offers a more comprehensive understanding of disease. It also provides innovative therapeutic avenues.
Nilo Therapeutics represents a bold venture. It combines elite scientific founders. It has experienced leadership. It possesses substantial financial backing. This formidable combination positions Nilo for success. The company is poised to make a profound impact. It aims to transform the treatment of immune-driven diseases. The launch of Nilo Therapeutics marks a significant milestone. It promises a future of restored immune balance. It offers new hope for patients worldwide.